wao logo


WAO News & Notes

September Medical Journal Review
九月医学杂志回顾
WAO Now: What's New in the World of WAO
今日WAO:WAO领域新进展
And In Other News . . .
其他新闻

September World Medical Journal Review

Prof. Richard F. Lockey, MD, WAO Web Editor-in-Chief, reviewed premier September medical journal articles for practicing allergists.
Richard
F. Lockey教授,医学博士,WAO网站主编,他为在业的变态反应科医生回顾了九月医学杂志的一些重要文章。

1. ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G (IgG) RESULTING FROM Fc SIALYLATION
IgG is both pro- and anti-inflammatory via engagement of its Fc fragment (Fc) with distinct Fcγ receptors (FcγRs). Some Fc-FcγR interactions generate pro-inflammatory effects of immune complexes and cytotoxic antibodies, however, in contrast, therapeutic IVIG and its Fc fragments are anti-inflammatory. These authors demonstrate that IgG acquires anti-inflammatory properties upon Fc sialylation, which is reduced upon the induction of an antigen-specific immune response. This differential sialylation may provide a switch from innate anti-inflammatory activity in the steady state to generating adaptive pro-inflammatory effects upon antigenic challenge. This study suggests that another type of difference between antibody molecules, determined by sequences of attached oligosaccharides, may be crucial for antibody function. Editor’s comment: The sugar moieties attached to the Fc fragment of IgG alter its activity. This knowledge may be useful in designing therapies for IVIG. This is exciting and innovative research and must reading for all allergists/immunologists. Kaneko Y, et al. Science 2006; 313: 670. Editorial by Burton DR, Dwek RA, p. 627.
译文
1. 免疫球蛋白G(IgG)Fc端涎酸化后产生抗炎活性
IgG通过其Fc片断与不同的Fcγ受体(FcγRs)结合,可以产生促炎活性,也可产生抗炎活性。一些免疫复合物和胞毒抗体的Fc-FcγR结合后能产生促炎活性,但与此相反,治疗用的IVIG及其Fc片断却具有抗炎活性。这些作者证实,IgG是通过Fc片断涎酸化,减弱了诱导抗原特异性的免疫反应,从而获得了抗炎活性。这种特殊的涎酸化可以在抗原刺激时将稳态的先天抗炎活性转化生成适应性的促炎效应。这项研究表明,不同抗体分子之间还存在着另外一种类型的区别,这种区别是由不同的糖基化造成的,而这对于抗体功能而言可能是至关重要的。编者按:IgG的Fc片断经过糖基化后可以改变其活性。这可能有助于今后研究设计治疗用的IVIG。所有的变态反应学家/免疫学家都应该了解这项令人激动的、创新性的研究成果。Kaneko Y, et al. Science 2006; 313: 670. Editorial by Burton DR, Dwek RA, p. 627.

2. MAST CELLS (MC's) CAN ENHANCE RESISTANCE TO SNAKE AND HONEYBEE VENOMS
It has been proposed that activation of MC's by snake or insect venoms can contribute to increased morbidity and mortality. However, the authors demonstrate that MC's can significantly reduce snake-venom-induced pathology in mice, at least in part by releasing carboxypeptidase A and possibly other proteases, which degrade venom components. MC's also significantly reduce the morbidity and mortality induced by honeybee venom. Editor’s comment: MC's mediators can be beneficial or detrimental to the host. Metz M, et al. Science 2006; 313: 526.
译文
2. 肥大细胞(MC's)能增强对蛇毒和蜜蜂毒液的抵抗性
以前人们认为,被蛇毒或昆虫毒液活化后的肥大细胞能增加这类疾病的发病率和死亡率。但作者研究证实,在小鼠中,肥大细胞能显著减轻蛇毒诱导的病理学改变,其中至少有部分是通过释放能降解毒液组分的羧肽酶A及其他可能的蛋白酶来实现的。肥大细胞同样也能显著降低蜜蜂毒液诱发疾病的发病率和死亡率。编者按:对宿主而言,肥大细胞的介质有利有弊。Metz M, et al. Science 2006; 313: 526.

3. EFFECTS OF A LEUKOTRIENE RECEPTOR ANTAGONIST (LTRA) ON EXHALED LEUKOTRIENE E4 (LTE4) AND PROSTANOIDS IN CHILDREN WITH ASTHMA
This open-label study with oral montelukast (5 mg once d for 4 wk) in 17 atopic children with asthma and 16 atopic children without asthma was designed to study the effects of LTRA on exhaled LTE4 and prostanoids in children with asthma vs controls. Pretreatment exhaled LTE4 (P < .0001) and 8-isoprostane (P < .0001) values were higher in asthmatics than those without asthma. Montelukast reduced exhaled LTE4 by 33% (P < .001) in patients with asthma and the reduction was correlated with pretreatment LTE4 values (r = -0.90; P = .0001). Montelukast had no effect on exhaled LTE4 in atopic children without asthma or on exhaled 8-isoprostane and PGE2 in either group. Nitric oxide (NO) concentrations were reduced by 27% after montelukast in the asthma group. Editor’s comment: Is this a method to identify patients who are most responsive to LTRAs? Perhaps! Montuschi P, et al. J Allergy Clin Immunol 2006; 118: 347.
译文
3. 儿童哮喘患者中,白三烯受体拮抗剂(LTRA)对呼出气冷凝液中白三烯E4(LTE4)和前列腺素类化合物的影响
这是一项由17例特应性特质的哮喘儿童和16例特应性体质的非哮喘儿童参加的开放性研究,受试者口服孟鲁司特钠5 mg每天一次,连续4周,目的是为了观察LTRA治疗对哮喘儿童与对照儿童的呼出气冷凝液中白三烯E4(LTE4)和前列腺素类化合物的影响。治疗前,哮喘儿童与对照组相比,呼出气冷凝液中的LTE4(P<.0001)和8-异前列腺素(P < .0001)水平明显升高。孟鲁司特钠能降低哮喘患者呼出气体冷凝液中LTE4达33%(P<.001),这种下降程度是和治疗前的LTE4值相关的(r = -0.90;P =.0001)。孟鲁司特钠对非哮喘特应性儿童的呼出气体冷凝液中LTE4没有影响,对这两组患者呼出气冷凝液中的8-异前列腺素和PGE2没有影响。哮喘组中,孟鲁司特钠治疗能降低27%的一氧化氮(NO)浓度。 编者按:是不是可以通过这种方法鉴别出哪些患者对LTRAs具有最佳的反应性?也许有这种可能!Montuschi P, et al. J Allergy Clin Immunol 2006; 118: 347.

4. DURATION OF AIRBORNE FEL d 1 REDUCTION AFTER CAT WASHING
Twelve adult female American domestic short-hair and medium-hair cats were washed by the immersion technique (immersed in tap water to the level of their heads, pelts massaged for three minutes, followed by a three-minute immersion in fresh water and then towel dried) to determine duration of airborne Fel d 1 reduction after cat washing. These washings did result in a 4- to 5-fold decrease in Fel d 1 collection at three hours, with a return to baseline within one day after washing. The authors conclude that washings do result in significant Fel d 1 reduction, but the reductions are short lived. It is unlikely that the average cat owner will experience meaningful improvement in allergic symptoms with this environmental control method. Editor’s comment: Cat allergic individuals should eliminate cats from their homes. Nageotte C, et al. J Allergy Clin Immunol 2006; 118: 521.
译文
4. 给猫洗澡后空气中播散的FEL d 1的保持低水平的持续时间
为了测定给猫洗澡后空气中播散的Fel d 1保持低水平的持续时间,研究采用浸没技术(将猫浸入自来水并没至头部附近,搓揉皮毛3分钟,然后再换干净水浸泡3分钟,最后用毛巾擦干)给12只美国家庭的成人雌性短毛和中等长毛宠物猫进行洗澡。这种洗澡方法的确能使收集到的Fel d 1水平在洗澡后3小时内降低4至5倍,但在一天之内又会恢复到基线水平。作者结论指出,洗澡确实能明显降低Fel d 1水平,但维持时间很短。因此对于通常的养猫者来说,想要采用这种环境控制措施来达到明显改善过敏症状的目的是不太可能的。编者按:猫过敏患者应该避免养猫。Nageotte C, et al. J Allergy Clin Immunol 2006; 118: 521.

5. NO EFFECTS OF PROBIOTICS ON ATOPIC DERMATITIS (AD) IN INFANCY: A RANDOMIZED PLACEBO-CONTROLLED TRIAL
In this randomized, double-blind, placebo-controlled study, the clinical and immunological effects of two probiotics strains of bacteria on AD in infancy were assessed. After a 4-6 week baseline and double-blind, placebo-controlled challenge to diagnose cow’s milk allergy (CMA), and a 4-6 week baseline, infants less than five months old with AD received either a hydrolysed, whey-based formula as placebo (n = 17) or hydrolysed, whey-based formula supplemented either with Lactobacillus rhamnosus (n = 17) or Lactobacillus GG (n = 16) for three months. Only four infants were diagnosed with CMA and no clinical or immunologic effects of probiotic bacteria were evident. Editor’s comment: The controversy continues about probiotics in the treatment of AD. Brouwer ML, et al. Clin Exp Allergy 2006; 36: 899.
译文
5. 益生菌对患有特应性皮炎的婴儿没有疗效:随机双盲安慰剂对照临床试验
这是一项随机、双盲、安慰剂对照的临床研究,目的是为了评价2种益生菌菌株对AD婴儿的临床和免疫学治疗效果。
经过4-6周的基线期观察,并通过双盲安慰剂对照激发试验诊断牛奶过敏(CMA),在4-6周基线期后,5个月以内的AD婴儿患者随机接受补充Lactobacillus rhamnosus(n=17)或Lactobacillus GG(n=16) 的乳清蛋白水解配方奶粉,并以乳清蛋白水解配方奶粉作为对照(n=17),观察3个月。只有4例婴儿被诊断为CMA,且未发现益生菌有任何临床或免疫学治疗效果。编者按:益生菌在AD治疗中仍存在争议。Brouwer ML, et al. Clin Exp Allergy 2006; 36: 899.

6. RELATIVE CORTICOSTEROID INSENSITIVITY OF PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC's) IN SEVERE ASTHMA
PBMC's from patients with severe asthma (n = 16), as defined by the American Thoracic Society, were compared to nonsevere asthma (n = 19) and normal volunteers (n = 10) to determine the suppression of lipopolysaccharide (LPS)-induced cytokine release by dexamethasone (D). Baseline spontaneous or stimulated release of cytokines was similar among all groups, however, LPS-induced release of IL-1β (P < 0.03), IL-8 (P < 0.03), and macrophage inflammatory protein 1α (MIP-1α) (P < 0.003) was less suppressed by D in severe asthma. This phenomenon was associated with a reduction in nuclear histone deacetylase activity (P < 0.01), an important determinant of the inflammatory response and of corticosteroid responsiveness that parallels impaired corticosteroids sensitivity (CS). Editor’s comment: Diminished CS in severe asthma affects the PBMC's. Hew M, et al. Am J Respir Crit Care Med 2006; 174: 134.
译文
6. 重症哮喘外周血单个核细胞(PBMC's)对皮质激素相对不敏感
为了判断地塞米松(D)对脂多糖(LPS)诱导细胞因子释放的抑制功能,研究者收集了重症哮喘患者(根据美国胸科协会定义)(n=16)的PBMC's,并和非重症哮喘患者(n=19)及正常志愿者(n=10)的PBMc's作比较。在这三组中,基线时自发或刺激释放的细胞因子水平都是类似的,但在重症哮喘组中,地塞米松抑制脂多糖(LPS)诱导的IL-1β(P<0.03),IL-8(P<0.03)和巨噬细胞炎症蛋白1α(MIP-1α)(P<0.003)释放的程度较低。这种现象和核组蛋白脱乙酰基酶的活性下降有关(P<0.01),而这种酶就是决定炎症应答水平以及对皮质激素反应性,即皮质激素敏感性(CS)下降程度的一个重要因素。编者按:重症哮喘中CS下降影响到了PBMc's。Hew M, et al. Am J Respir Crit Care Med 2006; 174: 134.

7. SYSTEMIC CORTICOSTEROID (SC) THERAPY FOR ACUTE ASTHMA EXACERBATIONS
This is a nice summary of the management of acute asthma with systemic CS. The authors call for the early use of an IV, intramuscular or oral CS within one hour of arrival in the emergency department, shown to reduce admission rates by up to 60%. They state that there is no clear evidence to support any one route of SC administration over another and that the doses in a nine-study meta-analysis demonstrate that doses of >80mg/d methylprednisolone or its equivalent offer no therapeutic advantage in the initial management of acute severe asthma. Editor’s comment: A great review article on the use of SC for severe asthma exacerbations. Fiel SB, Vincken W. J of Asthma 2006; 43: 321.
译文
7. 全身性皮质激素(SC)治疗急性哮喘发作
这是一篇关于使用全身皮质激素管理急性哮喘的很优秀的总结性文章。作者发现在患者到急诊室1小时之内早期应用IV,肌肉注射或口服CS,最多能降低60%的住院率。同时没有确切的证据表明,这几种全身使用皮质激素的给药方式之间存在优劣之分,通过对9个研究的荟萃分析结果显示,在治疗急性重症哮喘时,起始剂量>80mg/日的甲基强的松龙或相当剂量不会有更好的治疗效果。编者按: 这是一篇关于重症哮喘急性加重时使用SC的优秀综述。Fiel SB, Vincken W. J of Asthma 2006; 43: 321.

8. CYTOKINES OR THEIR ANTAGONISTS FOR THE TREATAMENT OF ASTHMA
This review is about various cytokines or their antagonists as possible treatments for asthma. The use of human monoclonal antibodies against IL-5 and a recombinant human soluble IL-4 receptor have not proven successful in patients with persistent asthma. Neither has administration of the potential anti-inflammatory cytokines IL-12 and interferon-γ. Tumor necrosis factor (TNF)-α is important in the persistence of inflammation and in patients with severe oral steroid-dependent asthma. Soluble TNF-α receptor (anti-TNF-α) has demonstrated promising results. Editor’s comment: The magic cytokine or its antagonists are yet to be discovered, however, anti-TNF-α shows promise for severe asthma. O’Byrne PM. Chest 2006; 130: 244
译文
8. 用于哮喘治疗的细胞因子及其拮抗剂
这是一篇关于可能用于哮喘治疗的各种细胞因子及其拮抗剂。在持续哮喘患者中,使用抗IL-5的人单克隆抗体以及重组人可溶性IL-4受体治疗没有效果。而IL-12和γ干扰素这两种可能具有抗炎作用的细胞因子尚未用于治疗。在持续性炎症以及重症口服皮质激素依赖的哮喘患者中,肿瘤坏死因子(TNF)-α起着非常重要的作用。目前的研究显示,可溶性TNF-α受体(抗TNF-α抗体)可能是有一定前途的。编者按:具有魔力的细胞因子或他们的拮抗剂还有待人们去发现,但就目前而言,抗TNF-α抗体在重症哮喘治疗中是有前途的。O’Byrne PM. Chest 2006; 130: 244

9. OBESITY AND ASTHMA
Obesity leads to metabolic and cardiovascular diseases and may increase asthma risks. Animal experiments suggest that the airway inflammation response is enhanced by both endogenous and exogenous leptin, which is increased in obese humans and is also a central mediator of inflammation in obesity. Cross-sectional and prospective cohort studies in humans show a slight increased incidence and prevalence of asthma in obese subjects, however, body mass does not appear to be a significant modifier of severity. Editor’s comment: Obesity seems to increase the incidence and prevalence of asthma. Beuther DA et al. Am J Respir Crit Care Med 2006; 174: 112.
译文
9. 肥胖和哮喘
肥胖会导致代谢性疾病和心血管疾病,也可能增加哮喘的危险性。在肥胖个体中,一种关键性炎症介质,瘦素水平会增加。经动物试验证实,无论是内源性还是外源性瘦素都会增加气道的炎症反应。而关于人类的横断面研究以及前瞻性队列研究也显示,肥胖个体中哮喘的发病率和患病率也轻度增加,但体重指数与哮喘的严重程度之间没有明显的相关性。编者按:肥胖看来会增加哮喘的发病率和患病率。Beuther DA et al. Am J Respir Crit Care Med 2006; 174: 112.

10. HERBAL MEDICINES FOR THE TREATMENT OF COPD: A SYSTEMATIC REVIEW
This is a review of 14 randomized clinical trials of 14 different herbal medicines.The conclusions are that the effectiveness of herbal medications to treat COPD is not established beyond reasonable doubt and that evidence from randomized clinical trials is scarce and often methodologically weak. Editor’s comment: The combination of long acting beta agonists and ipatropium bromide is a treatment of choice for COPD. Guo R, et al. Eur Respir J 2006; 28: 330.
译文
10. 草药治疗COPD:一篇系统性的综述
这是一篇总结关于14种不同草药的14个随机临床试验的综述。作者结论认为,草药治疗COPD的效果仍值得怀疑,且很少有类似这种来自随机临床试验的证据,一般都存在研究方法学的问题。编者按:COPD可选用长效β激动剂和异丙托溴铵联合治疗。Guo R, et al. Eur Respir J 2006; 28: 330.


WAO Now: What's New in the World of WAO

今日WAO:WAO领域新进展

WAO-JSA International Session
WAO-JSA国际会议

The World Allergy Organization and the Japanese Society of Allergology will present a joint session titled 'New trends in treatment of allergic disease' during the Japanese Society of Allergology’s 56th Annual Meeting. ates.
在日本变态反应学会第56届年会期间,世界变态反应组织将和日本变态反应学会举办主题为“过敏性疾病治疗的新趋势”的联席会议。

Thursday, 2 November 2006
9:00 a.m. ‑ 11:30 a.m.
Tokyo International Forum
东京国际会议中心
2006年11月2日 星期四
9:00 a.m. - 11:30 a.m.

Chairpersons: Michael A. Kaliner and Takemasa Nakagawa
会议主席:Michael A. Kaliner 和 Takemasa Nakagawa

  • "New Trends in the Treatment of Asthma, Rhinitis and Sinusitis"
    Michael A.Kaliner
  • "Unmet needs and lack of response in the treatment of allergy and asthma: From noncompliance to pharmacogenetics"
    Lanny J.Rosenwasser
  • "From ARIA guidelines to InterAirways"
    Jean Bousquet
  • “哮喘、鼻炎和鼻窦炎治疗的新趋势”
    Michael A.Kaliner
  • “过敏性疾病和哮喘治疗中的不足和无反应性:从依从性不佳到遗传药理学”
    Lanny J.Rosenwasser
  • “从ARIA指南至气道间联系”
    Jean Bousquet


KAAACI-WAO Joint Congress 2006 & the 9th WPAS

2006年度KAAACI-WAO联合大会与第九届西太平洋变态反应专题会议(WPAS)

The Korean Academy of Asthma, Allergy and Clinical Immunology and World Allergy Organization Joint Congress 2006 and the 9th West Pacific Allergy Symposium will take place in Seoul, Korea, 3-5 November 2006, at the Grand Hilton Seoul.
2006年度的韩国哮喘,变态反应和临床免疫学会与世界变态反应组织的联合大会暨第九届西太平洋变态反应专题会议将于2006年11月3-5日在韩国首尔的首尔希尔顿大酒店举办。

WAO is excited to partner with KAAACI and WPAS and pleased that many members of the WAO Board of Directors will participate as invited speakers at the congress. The scientific program highlights some of the most significant developments in clinical and basic research in allergy and clinical immunology, and Seoul will be an exciting new venue for up and coming scientists to share these cutting-edge technologies and ideas.
WAO很高兴能和KAAACI及WPAS一起合作,同时对于很多WAO执委会成员受邀作为讲者参加此次会议感到非常荣幸。本次会议的学术重点是关于变态反应和临床免疫学领域临床及基础研究的一些最重要的研究进展。届时首尔将成为各位与会学者和专家分享这些最新技术和学术观点的新舞台。

WAO Board Presentations:
WAO委员会成员的讲演题目:

  • "Real life classification of allergic rhinitis"
    G. Walter Canonica
  • "Allergic rhinitis: A disease remodeling the upper airways?"
    Paul B. Van Cauwenberge
  • "Ocular allergy: Implications for the clinical immunologists"
    Connie H. Katelaris
  • "Global management of rhinitis, sinusitis and asthma: What's new?"
    Michael A. Kaliner
  • "Positioning of anti-IgE antibody in asthma"
    Bob Q. Lanier
  • "The impact of allergic rhinits on bronchial asthma"
    Ruby Pawankar
  • "Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria"
    Allen P. Kaplan
  • "New aspects of antihistamines in allergic skin disease"
    F. Estelle R. Simons
  • "Inhibition of RSV-induced inflammation using siRNA technique"
    Richard F. Lockey
  • "Pharmacogenetics of inhaled corticosteroid"
    Lanny J. Rosenwasser
  • "WHO-GARD: The global alliance against chronic respiratory diseases"
    Jean Bousquet
  • "Hot topics in allergic diseases"
    Takeshi Fukuda
  • “关于过敏性鼻炎的实际生活分类”
    G. Walter Canonica
  • “过敏性鼻炎:一种导致上气道重塑的疾病”
    Paul B. Van Cauwenberge
  • “眼变态反应:对于临床免疫学家的意义”
    Connie H. Katelaris
  • “鼻炎、鼻窦炎和哮喘全球管理:新进展”
    Michael A. Kaliner
  • “抗IgE抗体在哮喘治疗中的地位”
    Bob Q. Lanier
  • “过敏性鼻炎对支气管哮喘的影响”
    Ruby Pawankar
  • “慢性自身免疫性荨麻疹中致病IgG亚类的功能评价”
    Allen P. Kaplan
  • “抗组胺药在治疗过敏性皮肤疾病的新认识”
    F. Estelle R. Simons
  • “使用小干涉RNA(siRNA)技术抑制RSV诱导的炎症”
    Richard F. Lockey
  • “吸入皮质激素的遗传药理学”
    Lanny J. Rosenwasser
  • “WHO-GARD:全球抗慢性呼吸疾病联盟”
    Jean Bousquet
  • “过敏性疾病中的热点问题”
    Takeshi Fukuda

Click here for more information.
详细资料请点击此处


wafWorld Allergy Forum
世界变态反应论坛

The management of allergic emergencies is a major concern for allergists worldwide. Asthma, anaphylaxis and angioedema will all be reviewed during the upcoming World Allergy Forum Symposium scheduled for Sunday, 12 November 2006 – 8:30 a.m. – 10:00 a.m., at the American College of Allergy, Asthma and Immunology (ACAAI), Annual Scientific Meeting in the Pennsylvania Convention Center, Ballroom AB in Philadelphia, PA, USA.
对于全世界的变态反应学者来说,变态反应急症是最值得关注的一个问题。美国变态反应哮喘和免疫学会(ACAAI)计划于2006年11月12日(星期日)8:30 a.m.-10:00 a.m.,在学术年会召开期间举办世界变态反应论坛专题讨论会,会议将主要讨论哮喘、严重过敏反应和血管性水肿等,会议地点在美国宾夕法尼亚州费城的宾夕法尼亚会议中心Ballroom AB厅。

Michael A. Kaliner, President, WAO will moderate this program of renowned international speakers.
WAO主席Michael A. Kaliner将主持这次会议,并和多位国际知名讲者共同探讨这些问题。


bankok
World Allergy Congress 2007 Symposium

2-6 December 2006
Bangkok, Thailand

世界变态反应会议2007年度专题讨论会
2006年12月2-6日
泰国曼谷

'Global Issues in Allergy: Answers for a Worldwide Problem'
Allergic Emergencies

“变态反应的全球性问题:世界难题的解决方案“

变态反应急症


Acute and Severe Asthma
Bob Q. Lanier, North Texas Institute for Clinical Trials
Fort Worth, Texas, USA
急性和重症哮喘
北得克萨斯临床试验中心Bob Q. Lanier
美国德克萨斯州Fort Worth

Anaphylaxis: Causes and Treatments
Ruby Pawankar, Nippon Medical School
Tokyo, Japan
严重过敏反应:病因和治疗
日本医学院Ruby Pawankar
日本东京

Angioedema
Michael A. Kaliner, Institute for Asthma and Allergy
Wheaton, Maryland, USA
血管性水肿
哮喘和变态反应学会Michael A. Kaliner
美国马里兰州Wheaton

New WAO Conversation
新的WAO访谈

Hear Dr. Sally Wenzel share her knowledge on what makes a severe asthmatic different and how to adjust your thinking to manage these refractory patients.
Sally Wenzel医生将和大家分享他对重症哮喘特殊性的理解,向大家介绍如何改变思路管理这些难治性哮喘患者,详情请点击此处


Sign up for On-Line Journal Subscription –
在线杂志订阅申请-

WAO and Hogrefe & Huber Publishers are offering a limited number of free on-line subscriptions to Allergy & Clinical Immunology International - Journal of the World Allergy Organization for members in developing countries. If you are interested in receiving a complimentary, on-line subscription, please send an e-mail to info@worldallergy.org, noting "Free Journal Subscription" in the subject line, with the following details:

First name
Last name
Postal address
City, State/Province and postal code
Country
E-mail address
Name of Member Society

WAO和Hogrefe & Huber出版公司现为发展中国家的会员提供有限数量的《Allergy & Clinical Immunology International - Journal of the World Allergy Organization》免费在线订阅服务。如果您希望得到这份杂志的免费赠阅的电子版,请给我们发送e-mail至info@worldallergy.org,注意在信件的主题栏写“Free Journal Subscription”,并详细注明以下资料:

名字
姓氏
邮政地址
市,州/省和邮政编码
国家
E-mail地址
成员学会的名称


And In Other News

其他新闻

Allergy Book Reviews
变态反应书评

Mast cells in allergic diseases. Chemical Immunology and Allergy. Vol. 87
Editors: Saito, H.; Okayama, Y.
Karger Basel 2005
变态反应疾病中的肥大细胞。化学免疫学和变态反应(87卷)
主编:Saito, H.,Okayama, Y.
出版商:Karger Basel 2005

List Price: $178.25 USD
Available from: Karger
定价:178.25 美元
订购网址:Karger


Reviewer:
Ron Walls MD, PhD
University of Sydney, Sydney, NSW, Australia
书评作者:
澳大利亚新南威尔士州悉尼市悉尼大学
Ron Walls 医学博士,公共卫生博士

Description:
Mast cells were originally described by Paul Ehrlich in the 19th Century, and their role in the immediate allergic response is well-known. Their importance in the allergic reaction was reflected in a debate scheduled for a major meeting in Allergy some years back on whether mast cells or T cells were the most important cells in the allergic reaction! Less well recognized is their importance in other aspects of immunological reactions including innate immunity, angiogenesis and tissue remodelling. Mast cells are derived from haematopoietic progenitors in the bone marrow but spend their lives as tissue-dwelling effector cells.
说明:
Paul Ehrlich在19世纪首次描述了肥大细胞,如今关于肥大细胞在速发型过敏反应中的作用已是众所周知。几年前,在一个重要的变态反应学术会议上,曾安排了关于变态反应过程中肥大细胞还是T细胞是最重要的细胞的讨论会,由此也反映了肥大细胞在变态反应过程中的重要性。但人们对于肥大细胞在包括先天免疫,血管发生和组织重塑等其它方面的重要性认识不多。虽然肥大细胞来源于骨髓中的造血祖细胞,但他们是生活在组织中的效应细胞。

Purpose:
This book is designed to bring together the latest work on mast cells from their development through to their physiological functions. The contributors are active workers in the area and bring the most current information to their contributions. The information is detailed but presented in a readable and engaging form.
目的:
本书总结了关于肥大细胞从发育至其生理功能的最新研究成果。作者都是当前活跃在该领域的各位学者,他们为大家带来了最新进展。尽管内容非常丰富,但叙述的通俗易懂。

Audience:
This volume would be of most value to those who are working actively in the field of research or tertiary clinical practice or who are involved in teaching immunology and biology and want an up-to-date source of information about these interesting cells outside of their immediate area of interest.
读者:
这卷书主要面向以下读者:包括活跃在该领域的研究人员或临床实践工作者,讲授免疫学和生物学的教师,以及那些希望了解他们感兴趣的肥大细胞除了速发型反应以外其它最新研究成果。

Features:
There are comprehensive accounts of the regulation of mast cell development and activation. This is followed by a detailed description of mast cell factors and receptors and their roles in allergic and immunologic conditions. Their localization in airway smooth muscle bundles characterizes asthma. Their roles in airway smooth muscle hyperplasia and in airway remodeling in asthma and their involvement in allergic rhinitis are well covered. The model of “mast cell knock-in” mice and its contribution to understanding of late phase reactions and chronic allergic inflammation is well covered. The species differences in these cells are emphasized, and the point is made that one cannot extrapolate from mouse to human mast cells. This is one factor that has made the study of these cells so difficult.
特色:
本书对肥大细胞发育和活化进行了广泛深入的介绍。接着详细描述了肥大细胞的各种因子和受体以及它们在变态反应和免疫中作用。肥大细胞在气道平滑肌束中定植是哮喘特征性表现。文章也介绍了肥大细胞在哮喘的气道平滑肌增殖和气道重塑中的作用,此外也涉及了该细胞在过敏性鼻炎中作用。书中对肥大细胞基因敲除小鼠模型及其对于认识晚期相反应和慢性过敏性炎症的作用做了充分的说明。书中强调了肥大细胞在不同物种之间是有差别的,因此不能根据小鼠的研究结果来推断出人类肥大细胞的作用。这也是使得研究肥大细胞比较困难的一个原因。

Assessment:
The subject matter is presented lucidly, even to a non-specialist, and although a multi-author book, the quality of the presentations is uniformly very high. This is an authoritative account of our current knowledge of this fascinating cell, not only in immediate hypersensitivity reactions, but also in other aspects of the immune response. The book can be warmly recommended to researchers, teachers and clinicians who need ready access to an up-to-date, high level of scientific material, and to students about to embark on a postgraduate study of immunology or allergy. It is an important addition to the personal library of serious students and should be available for reference in libraries and in clinical and research departments.
评价:
本书条理清晰,即使对于非专业人事,也易于理解。尽管本书事由多位作者撰写的,但所有章节的质量都非常高。本书是当前对肥大细胞,这种令学者着迷的细胞认识水平的权威总结,不仅是在速发型超敏反应方面,而且还包括参与的其它方面的免疫反应。在此,相关的科研人员、教师、临床医生以及毕业后想要从事免疫学或变态反应学的学生,如果希望了解该领域的最新最先进的学术成果,我会非常热情的向大家推荐这本书。本书具有较高的参考价值,值得部分学生购买,图书馆以及临床和科研部门也值得收藏。


Immune System Disorders Sourcebook (Second Edition)

Edited by: Joyce Brennfleck Shannon
免疫系统疾病参考资料(第二版)
主编:Joyce Brennfleck Shannon

List Price: $78.00 USD
Available from: Omnigraphics
定价:78.00 美元
订购网址:Omnigraphics

Reviewer:
Roger W. Fox, MD
University of South Florida Health Sciences Center, Tampa, FL, USA
书评作者:
美国佛罗里达州坦帕市南佛罗里达大学卫生科学中心
Roger W. Fox,医学博士

Description:
The text is a compendium of brief reviews in each of the 86 chapters on basic consumer health information about many of the disorders of the immune system. These include immune system function and response, diagnosis of immune disorders, information about inherited immune diseases, acquired immune diseases and autoimmune diseases. The book covers a wide range of immune-related disorders, such as primary immunodeficiencies, acquired immunodeficiency syndrome, Lupus, multiple sclerosis, type 1 diabetes, rheumatoid arthritis and Graves disease. Treatments and coping skills for individuals with immune disorders are discussed. A valuable directory of organizations in Chapter 86 provides information and help for patients with immune disorders and their families.
说明: 
本书介绍了各种免疫系统疾病最基本的、卫生常识性的知识,共分为86章,每一章都是概括性的描述。内容包括免疫系统的功能和反应性,免疫性疾病的诊断,遗传性免疫性疾病、获得性免疫性疾病以及自身免疫性疾病的知识。本书涵盖了很多种类的免疫性相关疾病,例如原发性免疫缺陷,获得性免疫缺陷综合症,狼疮,多发性硬化,1型糖尿病,类风湿关节炎以及Graves病等。书中还介绍了免疫性疾病的治疗和自我管理方法。书中第86章列出了一个有较高参考价值的免疫性疾病社会团体名录,便于免疫性疾病患者及其家属了解各种信息并寻求帮助。

Purpose:
This text serves as a quick overview resource of a wide range of immunological disorders for patients and healthcare providers 
目的:
对于想要了解免疫性疾病的患者和健康护理人员而言,本书是一本内容广泛的、可以随时翻阅的、概括性的参考书。

Audience:
This sourcebook on the immune system disorders should find a home in many of the public and medical libraries as an important resource for individuals and specific support groups. Physicians’ offices could provide this text to patients and their families for general knowledge on immune problems and as a resource to find on-line information about various disorders.
读者: 
公共医学类的图书馆的馆藏图书中应该有这本免疫系统疾病的参考书籍,作为重要资料便于个人及专业人士阅览。内科医生的诊所也需要有这本藏书,这样就可以告诉患者及其家属有关免疫学问题的一般常识,同时参考这本书可以在线了解各种疾病知识。

Features:
The book has a directory of organizations with immune disorders information, complete with address, phone and FAX numbers and websites. 
特色:
本书列出了提供免疫性疾病相关信息的社会团体详细名录,包括地址、电话和传真号码及网址等。

Assessment:
This book is an excellent resource text for libraries and healthcare providers’ offices, plus support groups and patient advocates would find this book very helpful for medical information and for identifying national organizations with a focus on a specific immune disorder.
评价:
本书是图书馆和卫生保健机构的必备参考书,由于书中还列出了相关的社会援助机构,因此患者权益保护人士除了能够很容易的从中找到相关的医学信息,也能够了解到这些全国性的组织各自主要针对哪个特定的免疫性疾病。


Find more allergy book reviews on the WAO Website here.
WAO网站上其它的变态反应学书评见此处

The World Allergy Organization's mission is to build a global alliance of allergy societies to advance excellence in clinical care, research, education and training. Visit us on the Web at http://www.worldallergy.org/
世界变态反应组织的使命是建立一个全球性的变态反应学会联盟,不断推动临床、科研、教学与培训工作的进步。欢迎您浏览我们的网站: http://www.worldallergy.org/

World Allergy Organization (WAO)
Secretariat
555 E. Wells Street, Suite 1100
Milwaukee, WI 53202-3823
Email: info@worldallergy.org
世界变态反应组织(WAO)秘书处
555 E. Wells Street, Suite 1100
Milwaukee, WI 53202-3823
电子信箱:info@worldallergy.org


You have received this message because you are a member of a WAO Member Society, you have subscribed for the monthly e-letter or had previous contact with the World Allergy Organization. If you would prefer not to receive further messages from WAO, please reply to this message with REMOVE in the subject line.
您因如下原因收到此次通讯:您是世界变态反应协会会员,或者您曾向世界变态反应协会订阅过电子月刊,或者您以前曾与世界变态反应协会进行过有关联系。如果您不希望继续收到来自世界变态反应协会的信息,请以删除为主题回复此邮件。


Made possible through an unrestricted educational grant from Novartis.